

IFVW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.
Dated: September 15, 2004 Signature: Lynn L. Janulis
(Lynn L. Janulis)

Docket No.: 01017/40006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Steven S. Gill et al.

Application No.: 10/784,547

Filed: February 23, 2004

Art Unit: 1614

For: METHOD OF TREATING PARKINSON'S
DISEASE IN HUMANS BY
INTRAPUTAMINAL INFUSION OF GLIAL
CELL-LINE DERIVED NEUROTROPHIC
FACTOR

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, a Supplemental Information Disclosure Statement and a Form PTO/SB/08 are submitted herewith by the Applicants for consideration in connection with the above-identified patent application. All documents listed, A3-A4 and C31-C34, on the Form PTO/SB/08 are enclosed herewith.


In accordance with 37 C.F.R. § 1.97(e), each item of information contained in the Form PTO/SB/08 was first cited in the International Search Report from the European Patent Office (International Search Authority) in a counterpart PCT application (PCT/US2004/005063) less than three months prior to filing of this Supplemental Information Disclosure Statement. The Applicants request that these documents be made of official record in the above-identified patent application and considered by the Examiner during examination of said application.

This Supplemental Information Disclosure Statement is not intended to be an admission that this art is relevant, or that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. § 102 and § 103.

No fee is required for submission of this statement because each new item of information was first cited in a counterpart PCT International Application and no item of information was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement. Should the Patent Office determine that a fee is due for consideration of this Supplemental Information Disclosure Statement, however, the Patent Office is hereby authorized to charge that fee to Deposit Account 13-2855. A copy of this paper is enclosed.

Dated: September 15, 2004

Respectfully submitted,

By  _____

Lynn L. Janulis

Registration No.: 53,066

Agent for Applicants


MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/784,547
				Filing Date	February 23, 2004
				First Named Inventor	Steven S. Gill
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	01017/40006

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A3	5,731,284	03-24-1998	Williams	
	A4	2001/0027599	10-11-2001	Elsbert	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C31	International Search Report for International Application No. PCT/US2004/005063 (September 7, 2004).	
	C32	GILL et al., "Intraparenchymal putaminal administration of glial-derived neurotrophic factor in the treatment of advanced Parkinson's disease," <i>Neurology</i> , A241:58 (2002).	
	C33	BRUNDIN, "GDNF treatment in Parkinson's disease: Time for controlled clinical trials?," <i>Brain</i> , 125:2149-2151 (2002).	
	C34	GRONDIN et al., "Glial cell line-derived neurotrophic factor (GDNF): A drug candidate for the treatment of Parkinson's disease," <i>J. Neurol</i> 245:P35-P42 (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--